IMEIK(SZ:300896) Xin Lang Zheng Quan·2025-10-29 12:56Core Insights - Aimeike is a leading player in the domestic medical aesthetics industry, focusing on the research and development of biological medical soft tissue repair materials, with strong technical barriers and product matrix advantages [1] Financial Performance - In Q3 2025, Aimeike reported revenue of 1.865 billion yuan, ranking second in the industry, while the industry leader, Huaxi Biological, achieved revenue of 3.163 billion yuan [2] - The company's net profit for the same period was 1.107 billion yuan, ranking first in the industry, with the second-ranked Jinbo Biological reporting a net profit of 565 million yuan [2] Financial Ratios - Aimeike's debt-to-asset ratio stood at 8.20% in Q3 2025, significantly lower than the industry average of 16.58%, indicating strong solvency [3] - The gross profit margin for the same period was 93.36%, higher than the industry average of 84.95%, reflecting robust profitability [3] Executive Compensation - Chairman Jian Jun's salary decreased from 2.5144 million yuan in 2023 to 2.49 million yuan in 2024, a reduction of 24,400 yuan [4] - General Manager Shi Yifeng's salary also saw a decrease from 2.955 million yuan in 2023 to 2.69 million yuan in 2024, a reduction of 265,000 yuan [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.10% to 56,300, while the average number of circulating A-shares held per shareholder increased by 0.10% to 3,704.54 [5] - Major shareholders, including Hong Kong Central Clearing Limited and various ETFs, have reduced their holdings [5] Business Highlights - Aimeike completed the acquisition of a controlling stake in South Korea's Regen Company, expanding its international market presence [5] - The company's subsidiary, Beijing Nobomin, received certification for Minoxidil topical solution, marking a significant milestone in product development [5] - Ongoing clinical trials for products like the second-generation implant line and the Sumei injection are expected to progress towards registration by the end of 2025 [5]